Dr. Jennifer Springer, MD
Emergency Medicine (Emergency Medicine Physician)
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Emergency Medicine Physician primary
FL license ME0078659
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 2 companies reported 16 payments worth $1,851 in total to this clinician.
| Merck Sharp & Dohme LLC | $1,324 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $527 |
| Travel and Lodging | $1,243 |
|---|---|
| Food and Beverage | $608 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Jun 23, 2025 | Travel and Lodging NEUROSCIENCE · travel to Rosemont, IL · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $337 |
| E.r. Squibb & Sons, L.l.c. Jul 29, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $270 |
| E.r. Squibb & Sons, L.l.c. Nov 25, 2025 | Travel and Lodging travel to Miami, FL · in-kind | $257 |
| Merck Sharp & Dohme LLC Jun 23, 2025 | Travel and Lodging NEUROSCIENCE · travel to Rosemont, IL · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $181 |
| Merck Sharp & Dohme LLC Jun 24, 2025 | Travel and Lodging NEUROSCIENCE · travel to Rosemont, IL · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $181 |
| Merck Sharp & Dohme LLC Aug 7, 2025 | Travel and Lodging NEUROSCIENCE · travel to Rosemont, IL Company’s descriptionProvided as part of a clinical research engagement. | $16.50 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 2 companies. The companies reported $619,429 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (Targe…
E.r. Squibb & Sons, L.l.c. - A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease
Janssen Research & Development, LLC - Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT05980949 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimer…
E.r. Squibb & Sons, L.l.c. - A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06126224 - A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06976203
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.